Anti-tumour necrosis factor therapy in Crohn's disease: where are we now?
van Deventer
S J H
SJ
Department of Experimental Medicine, Academic Medical Centre, Meibergdreef 9, 1105 AZ Amsterdam, the Netherlands. S.J.vanDeventer@amc.uva.nl
D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use*; D017209:Apoptosis; D002352:Carrier Proteins / Q000627:therapeutic use*; D003424:Crohn Disease / Q000188:drug therapy*; D005260:Female; D005765:Gastrointestinal Agents / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D000069285:Infliximab; D011247:Pregnancy; D011248:Pregnancy Complications / Q000188:drug therapy; D018124:Receptors, Tumor Necrosis Factor; D047888:Receptors, Tumor Necrosis Factor, Type I; D014376:Tuberculosis / Q000139:chemically induced; D053319:Tumor Necrosis Factor Decoy Receptors; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
D000911:Antibodies, Monoclonal; D002352:Carrier Proteins; D005765:Gastrointestinal Agents; D018124:Receptors, Tumor Necrosis Factor; D047888:Receptors, Tumor Necrosis Factor, Type I; D053319:Tumor Necrosis Factor Decoy Receptors; D014409:Tumor Necrosis Factor-alpha; C069521:recombinant human tumor necrosis factor-binding protein-1; D000069285:Infliximab